Linrodostat

• UNSPSC Description:

  Linrodostat (BMS-986205) is a selective and irreversible indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 value of 1.1 nM in IDO1-HEK293 cells. Linrodostat is well tolerated with potent pharmacodynamic activity in advanced cancers[1][2].

• Target Antigen:

  Indoleamine 2,3-Dioxygenase (IDO)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/BMS-986205.html

• Purity:

  99.81

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=CC=C(Cl)C=C1)[C@H](C)[C@@](CC2)([H])CC[C@H]2C3=CC=NC4=C3C=C(F)C=C4

• Molecular Weight:

  410.91

• References & Citations:

  [1]Richards T, et al. Cell based functional assays for IDO1 inhibitor screening and characterization. Oncotarget. 2018 Jul 20;9(56):30814-30820.|[2]Lillian L. Siu, et al. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. AACR; Cancer Res. 2017; 77 (13 Suppl): Abstract nr CT116.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  1923833-60-6